Potentiation of the mutagenicity and recombinagenicity of bleomycin in yeast by unconventional intercalating agents.
Interactions between bleomycin (BLM) and conventional or unconventional intercalating agents were analyzed in an assay for mitotic gene conversion at the trp5 locus and reversion of the ilv1-92 allele in Saccharomyces cerevisiae strain D7. BLM is a potent recombinagen and mutagen in the assay. Various chemicals modulate the genetic activity of BLM, producing either antimutagenic effects or enhanced genotoxicity. Effects of cationic amino compounds include enhancement of BLM activity by aminoacridines and protection against BLM by aliphatic amines. The potentiation of BLM is similar to findings in a micronucleus-based BLM amplification assay in Chinese hamster V79 cells. In this study, the amplification of BLM activity was explored in yeast using known intercalators, compounds structurally related to known intercalators, and unconventional intercalators that were identified on the basis of computer modeling or results in the Chinese hamster BLM amplification assay. As shown in previous studies, the classical intercalator 9-aminoacridine (9AA) caused dose-dependent enhancement of BLM activity. Other compounds found to enhance the induction of mitotic recombination and point mutations in strain D7 were chlorpromazine, chloroquine, mefloquine, tamoxifen, diphenhydramine, benzophenone, and 3-hydroxybenzophenone. The increased activity was detectable by cotreatment of yeast with BLM and the modulator compound in growth medium or by separate interaction of the intercalator with DNA followed by BLM treatment of nongrowing cells in buffer. The data support the interpretation drawn from micronucleus assays in mammalian cells that BLM enhancement results from DNA intercalation and may be useful in detecting noncovalent interactions with DNA. Environ.
Hoffmann
George R
GR
Department of Biology, College of Holy Cross, Worcester, Massachusetts 01610-2395, USA. ghoffmann@holycross.edu
Laterza
Amanda M
AM
Sylvia
Katelyn E
KE
Tartaglione
Jason P
JP
D000588:Amines / Q000494:pharmacology; D000818:Animals; D001577:Benzophenones / Q000494:pharmacology; D001761:Bleomycin / Q000494:pharmacology*; D002460:Cell Line; D002738:Chloroquine / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D006224:Cricetinae; D004249:DNA Damage; D004357:Drug Synergism; D005785:Gene Conversion / Q000187:drug effects; D007364:Intercalating Agents / Q000494:pharmacology*; D015767:Mefloquine / Q000494:pharmacology; D009152:Mutagenicity Tests; D009153:Mutagens / Q000494:pharmacology*; D011995:Recombination, Genetic / Q000187:drug effects*; D012441:Saccharomyces cerevisiae / Q000187:drug effects* / Q000235:genetics; D013629:Tamoxifen / Q000494:pharmacology
D000588:Amines; D001577:Benzophenones; D007364:Intercalating Agents; D009153:Mutagens; D013629:Tamoxifen; D001761:Bleomycin; C047723:benzophenone; D002738:Chloroquine; D015767:Mefloquine; D002746:Chlorpromazine